Repros Therapeutics Inc. Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal® Clinical Program

January 7, 2013 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

THE WOODLANDS, Texas, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a clinical update of its Androxal® Phase 3 program.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase III